Literature DB >> 11011341

Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements.

A Jeremias1, R J Whitbourn, S D Filardo, P J Fitzgerald, D J Cohen, E M Tuzcu, W D Anderson, A A Abizaid, G S Mintz, A C Yeung, M J Kern, P G Yock.   

Abstract

BACKGROUND: Fractional flow reserve (FFR) is a measure of coronary stenosis severity that is based on pressure measurements obtained at maximal hyperemia. The most widely used pharmacologic stimulus for maximal coronary hyperemia is adenosine, administered either as a continuous intravenous (IV) infusion or intracoronary (IC) bolus. IV adenosine has more side effects and is more costly than IC adenosine but has a more stable and prolonged hyperemic effect.
METHODS: We compared the efficacy of IC and IV adenosine administration for the measurement of FFR in a multicenter trial. Fifty-two patients with 60 lesions underwent determination of FFR with both IV and IC adenosine. IV adenosine was administered as a continuous infusion at a rate of 140 microgram/kg per minute until a steady state hyperemia was achieved. IC adenosine boluses were administered at a dose of 15 to 20 microgram in the right and 18 to 24 microgram in the left coronary artery. FFR was calculated as the ratio of the distal coronary pressure (from pressure guide wire) to the aortic pressure (guide catheter) at maximal hyperemia.
RESULTS: A total of 26 left anterior descending, 23 right, 9 left circumflex, and 3 left main coronary arteries were evaluated. Mean percent stenosis for both groups was 55.8% +/- 23.6% (range 0% to 95%), and mean FFR was 0.78 +/- 0.15 (range 0.41 to 0.98). There was a strong and linear correlation between FFR measurements with IV and IC adenosine (R = 0.978, y = 0. 032 + 0.964x, P <.001). The agreement between the 2 sets of measurements was also high, with a mean difference in FFR of -0.004 +/- 0.03. However, a small random scatter in both directions of FFR measurements was noted with 5 lesions (8.3%) where FFR with IC adenosine was higher by 0.05 or more compared with IV infusions, suggesting a suboptimal hyperemic response in these patients. Changes in heart rate and blood pressure were significantly higher with IV adenosine. Two patients with IV, but none with IC adenosine, had severe side effects (bronchospasm and severe nausea).
CONCLUSION: These results suggest that IC adenosine is equivalent to IV infusion for the determination of FFR in the majority of patients. However, in a small percentage of cases, coronary hyperemia was suboptimal with IC adenosine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11011341     DOI: 10.1067/mhj.2000.109920

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  22 in total

1.  Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.

Authors:  Janet Wei; Puja K Mehta; B Delia Johnson; Bruce Samuels; Saibal Kar; R David Anderson; Babak Azarbal; John Petersen; Barry Sharaf; Eileen Handberg; Chrisandra Shufelt; Kamlesh Kothawade; George Sopko; Amir Lerman; Leslee Shaw; Sheryl F Kelsey; Carl J Pepine; C Noel Bairey Merz
Journal:  JACC Cardiovasc Interv       Date:  2012-06       Impact factor: 11.195

2.  Optical coherence tomography criteria for defining functional severity of intermediate lesions: a comparative study with FFR.

Authors:  Tomasz Pawlowski; Francesco Prati; Tomasz Kulawik; Eleonora Ficarra; Jacek Bil; Robert Gil
Journal:  Int J Cardiovasc Imaging       Date:  2013-09-03       Impact factor: 2.357

3.  Differences between automatically detected and steady-state fractional flow reserve.

Authors:  Tobias Härle; Sven Meyer; Felix Vahldiek; Albrecht Elsässer
Journal:  Clin Res Cardiol       Date:  2015-07-25       Impact factor: 5.460

4.  A simplified formula to calculate fractional flow reserve in sequential lesions circumventing the measurement of coronary wedge pressure: The APIS-S pilot study.

Authors:  Juan Luis Gutiérrez-Chico; Carlos Cortés; Miłosz Jaguszewski; Michele Schincariol; Ignacio J Amat-Santos; Juan A Franco-Peláez; Grzegorz Żuk; Dariusz Ciećwierz; Wojciech Wojakowski; Felipe Navarro; Shengxian Tu; Borja Ibáñez
Journal:  Cardiol J       Date:  2019-07-01       Impact factor: 2.737

5.  Comparison of standard- and high-dose intracoronary adenosine for the measurement of coronary fractional flow reserve (FFR).

Authors:  Jens Röther; Stephan Achenbach; Monique Tröbs; Florian Blachutzik; Holger Nef; Mohamed Marwan; Christian Schlundt
Journal:  Clin Res Cardiol       Date:  2016-06-15       Impact factor: 5.460

6.  Fractional Flow Reserve: Does a Cut-off Value add Value?

Authors:  Shah R Mohdnazri; Thomas R Keeble; Andrew Sp Sharp
Journal:  Interv Cardiol       Date:  2016-05

7.  Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.

Authors:  Carl J Pepine; R David Anderson; Barry L Sharaf; Steven E Reis; Karen M Smith; Eileen M Handberg; B Delia Johnson; George Sopko; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

8.  The adult Göttingen minipig as a model for chronic heart failure after myocardial infarction: focus on cardiovascular imaging and regenerative therapies.

Authors:  Karl H Schuleri; Andrew J Boyle; Marco Centola; Luciano C Amado; Robert Evers; Jeffrey M Zimmet; Kristine S Evers; Katherine M Ostbye; Diana G Scorpio; Joshua M Hare; Albert C Lardo
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

Review 9.  Coronary Physiology Assessment for the Diagnosis and Treatment of Stable Ischemic Heart Disease.

Authors:  Ali E Denktas; David Paniagua; Hani Jneid
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

Review 10.  Fractional flow reserve as a surrogate for inducible myocardial ischaemia.

Authors:  Tim P van de Hoef; Martijn Meuwissen; Javier Escaned; Justin E Davies; Maria Siebes; Jos A E Spaan; Jan J Piek
Journal:  Nat Rev Cardiol       Date:  2013-06-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.